Kangtai biology expects the net profit in the first half of this year to fall by at least 60%< Br > < div class= "contheight" > < / div > on July 24, Shenzhen Kangtai Biological Products Co., Ltd. (Kangtai biological, 300601) issued a semi annual performance forecast for this year, saying that the net profit attributable to shareholders of Listed Companies in the first half of the year was 100 million to 130 million yuan, a decrease of 70.29% to 61.37% over the same period last year; Deduct non net profit of 65.9022 million yuan to 95.9022 million yuan, a decrease of 77.74% to 67.61% over the same period last year< Img alt= "semi annual report forecast data of Kangtai biology" style= "width:600px;" src=" https://imagecloud.thepaper.cn/thepaper/image/207/486/128.png ">
semi annual report forecast data of Kangtai biology
for the reason for the sharp decline in net profit, Kangtai biology said that the main reason was the impairment of assets related to covid-19 inactivated vaccine and the expensing of phase III clinical expenditure. Or affected by the above news, the share price of Kangtai biology fell sharply on July 25, with a maximum decline of more than 9%. As of noon, it fell 6.41% to 35.75 yuan / share, with a market value of 40.06 billion yuan.
< div class=" contheight "> < / div > Kangtai biology introduced in the latest performance forecast that since the second quarter, the vaccination environment of covid-19 at home and abroad has changed greatly, the demand for covid-19 vaccine has decreased rapidly, and the sales volume of covid-19 vaccine of the company has declined rapidly; the company’s covid-19 inactivated vaccine is still in the phase III clinical stage overseas, and the uncovering of phase III clinical data in Ukraine has been delayed due to the impact of the Russian Ukrainian war, and the subsequent sales have great uncertainty.
the three covid-19 vaccines distributed by Kangtai biology < / P > the first is inactivated vaccine: on September 29, 2020, Kangtai biology announced that its new covid-19 inactivated vaccine obtained the approval of clinical trials. The vaccine was urgently used in China in May 2021, and has since been approved for homologous enhanced immunization; the second is adenovirus vector vaccine: in August 2020, Kangtai biology and AstraZeneca signed an exclusive licensing cooperation framework agreement for the mainland Chinese market , actively promote the R & D, production, supply and commercialization of the chadox1 adenovirus vector vaccine cooperated by AstraZeneca and Oxford University in the Chinese mainland market through technology transfer; The third is recombinant VSV vector vaccine. In September 2020, when it was disclosed that the inactivated vaccine was approved for clinical trials, Kangtai biology mentioned that the vaccine was in the pre clinical research stage< Br > < div class= "contheight" > < / div > although the inactivated vaccine of Kangtai biology has been launched in China in the middle of 2021, Kangtai biology has not disclosed the data related to the batch issuance or sales of covid-19 vaccine in the 2021 annual report, this year’s first quarter report and the latest semi annual report< Br > < div class= "contheight" > < / div > the 2021 annual report shows that the company’s recombinant novel coronavirus vaccine (Y25 adenovirus vector) obtained the emergency use authorization from the national drug and food administration of Indonesia in October 2021, and achieved export. On July 25, the reporter contacted Kangtai biosecurities department as an investor. The staff said on the phone that the recombinant novel coronavirus vaccine (Y25 adenovirus vector) is the new coronavirus vaccine cooperated with AstraZeneca. As for the recombinant VSV vector vaccine, there is no new progress. At present, the company mainly promotes two new coronavirus vaccines, inactivated and adenovirus vector< Br > < div class= "contheight" > < / div > according to the latest performance forecast, the performance of Kangtai biology is affected by the research and development of covid-19 vaccine. The above staff said that it is not clear whether the company will reduce its investment in covid-19 vaccine in the future.